Developer docs
API playgroundTry for free, no card

Search company profiles

KCCure

Full company profile

uuid00sr7oi

Namestring
KCCure
Legal namestring
Kidney Cancer Research Alliance
Websiteurl
kccure.org
Company typeenum
Private
Founded yearint
2016
Descriptiontext

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit patient advocacy organization founded in 2016 to accelerate kidney cancer research and improve outcomes for patients across all renal cell carcinoma subtypes. The organization serves kidney cancer patients, caregivers, researchers, and clinicians by aggregating educational content, subtype-specific patient communities, clinical trial information, and patient-reported survey data. Cofounded by patients, caregivers, and clinicians — including President Dena Battle and Vice President Dr. Hans Hammers (UT Southwestern) — KCCure operates as a grassroots coalition emphasizing patient-driven, evidence-based advocacy.

The organization's product portfolio spans six interconnected offerings: subtype-specific Facebook patient communities (covering metastatic, localized, papillary, chromophobe, translocation, unclassified RCC, and renal medullary carcinoma); a peer-reviewed research grants program with the Chromophobe RCC Research Program as a flagship ($50,000 annual grants); comprehensive educational resources covering types, stages, grades, adjuvant therapy, and treatments; a non-clear cell RCC clinical trial database; a patient survey research platform whose data has been presented at ASCO and ESMO; and an FDA-approved treatment reference chart. KCCure does not develop proprietary technology; its "platform" is kccure.org supplemented by Facebook groups, functioning as an information aggregation and community hub rather than a technology product.

KCCure's business model is donation-driven: contributions from individuals via website and Facebook campaigns fund both operations and research grants. Notable grant awards include a $100,000 inaugural CAR T-Cell grant to Dana Farber (2017) and recurring $50,000 Chromophobe RCC grants to Brigham and Women's Hospital researchers (FY2022, FY2024). All resources — education, trial listings, community access, grant programs — are provided free. Distribution is entirely direct-to-patient through digital channels globally, with strategic partnerships (Eisai's Kompass hub, Broad Institute's Rare Cancer Dependency Map, RCRF's Pattern.org) extending reach into pharma, research, and tissue-donation ecosystems. The go-to-market motion is community-led: building subtype-specific patient communities, engaging patients in survey research, and amplifying the patient voice at major oncology conferences.

Short descriptiontext

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit founded in 2016 providing free kidney cancer education, subtype-specific patient communities, clinical trial databases, and peer-reviewed research grants to patients, caregivers, and researchers across all RCC subtypes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLeesburg, United States
HQ citystring
Leesburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
kidney cancer advocacy, patient education resources, research grant funding, patient community support, clinical trial information
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGACAL
Public Health & Health Equity Organizations
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Social Advocacy Organizations8133
SIC code2 codes
  • Services-Health Services8000
  • Services-Membership Organizations8600
Product category
Patient Advocacy Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations
TypeAffiliate Referral
Description

KCCure operates as a 501(c)(3) non-profit organization and raises funds through individual donations, Facebook donation campaigns, and its website donation portal. Donations fund the organization's research grant programs, outreach activities, and operational costs.

kccure.org
2Research Grants (Funded by Donations)
TypeProfessional Services
Description

KCCure funds peer-reviewed kidney cancer research grants using donated funds. The organization has awarded grants including a $100,000 inaugural grant to Dana Farber (CAR T-Cell research) and $50,000 Chromophobe RCC research grants to Brigham and Women's researchers.

kccure.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Others, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit that provides free kidney cancer patient education resources, subtype-specific online patient communities, peer-reviewed research grant funding (including the Chromophobe RCC Research Program), a non-clear cell clinical trial database, and patient survey research to inform research priorities. The organization aggregates and shares kidney cancer information through its website, Facebook communities, and partnerships with advocacy organizations and pharmaceutical companies. All resources are provided free of charge to patients and caregivers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Chromophobe patient community grew by more than 70 percent since the KCCure Chromophobe Program launched in 2020
+3 more records
Product overview1 text field

KCCure (Kidney Cancer Research Alliance) is a patient-driven, evidence-based kidney cancer advocacy organization offering a suite of interconnected resources including online patient communities for different RCC subtypes, a peer-reviewed research grants program with focus areas like Chromophobe RCC, educational materials on types/stages/treatments, a clinical trial database for non-clear cell subtypes, patient survey research, and an FDA-approved treatment reference chart. The organization operates as a grassroots coalition connecting patients, caregivers, doctors, and researchers to accelerate kidney cancer research and improve patient outcomes.

Product and service6 records
1KCCure Patient Communities
CategoryPatient community / peer support service
Description

Online patient communities (primarily Facebook groups) connecting individuals diagnosed with specific kidney cancer subtypes — including clear cell, papillary, chromophobe, translocation, unclassified, renal medullary carcinoma, and localized/metastatic categories — for peer support, information sharing, and clinical trial referrals.

2KCCure Research Grants Program
CategoryResearch grant funding program
Description

Peer-reviewed research funding program enabling patients to direct competitive research grants to patient-prioritized kidney cancer research gaps, including the Chromophobe RCC Research Program offering $50,000 awards and the inaugural $100,000 CAR T-Cell grant to Dana Farber.

3Kidney Cancer Education Resources
CategoryPatient education service
Description

Free educational materials covering kidney cancer types, stages, grades, treatment options, adjuvant therapy, clinical trials, and a glossary of terms, provided to patients and caregivers through the KCCure website.

4Non-Clear Cell RCC Clinical Trial Database
CategoryClinical trial information service
Description

Comprehensive listing of active and enrolling clinical trials specifically for non-clear cell renal cell carcinoma subtypes, including NCT trial IDs, histology, treatments, phases, and locations, published on the KCCure website.

5Patient Survey Data Platform
CategoryPatient-reported outcomes research service
Description

Patient-driven survey research program including the 2019 Kidney Cancer Patient Survey, COVID-19/Kidney Cancer Patient Survey, and COVID-19 Vaccine surveys, generating patient-reported outcome and treatment-preference data that informs research priorities and is presented at major oncology conferences.

6FDA-Approved Kidney Cancer Treatment Chart
CategoryTreatment reference resource
Description

Reference chart listing all FDA-approved treatments for metastatic renal cell carcinoma with brand/generic names, drug companies, approval dates, and line of therapy information, published as a free resource on the KCCure website.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Eisai
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Eisai partnered with KCCure and three other advocacy organizations (KidneyCAN, Kidney Cancer Association, National Kidney Foundation) to launch Kompass, an unbranded digital hub that aggregates kidney cancer support resources for patients and caregivers. The platform features around four dozen resources including educational guides, videos, helplines, peer mentoring, and patient testimonials, personalized based on user responses to three questions about their role and needs. KCCure contributed its expertise in patient-centered resources and community needs to this initiative.

fiercepharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

KidneyCAN is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers. KCCure and KidneyCAN contributed to the aggregation of support resources on the platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

The Kidney Cancer Association is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers, providing educational resources and support materials on the platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

The National Kidney Foundation is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers, contributing kidney cancer support resources to the platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-29
Description

KCCure awarded Dr. Elizabeth Henske and Dr. Carmen Priolo from Brigham and Women's Hospital the FY2022 KCCure Chromophobe Research Grant of $50,000 for their proposal: Role of Cysteine Homeostasis and Ferroptosis in the Therapy of Chromophobe RCC. This grant is part of the KCCure Chromophobe RCC Research Program. Dr. Henske received a second grant in 2024 for Targeting KIT in Chromophobe Kidney Cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-06-22
Description

KCCure awarded its inaugural research grant of $100,000 to Dr. Wayne Marasco at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures. This was described as a milestone for KCCure and for kidney cancer research as a whole.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

KCCure's Director of Patient Engagement Laura Loughlin attended the Broad Institute's Pre-Launch Workshop for the Rare Cancer Dependency Map Initiative. The initiative provides a patient-driven research platform seeking treatments for rare kidney cancers. KCCure promotes and supports this research effort as part of its mission to advance rare subtype research.

8Rare Cancer Research Foundation (RCRF)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

KCCure partners with the Rare Cancer Research Foundation (RCRF) and promotes Pattern.org, an online patient-directed consent platform that allows patients to authorize donation of fresh tumor tissue for research. KCCure actively encourages eligible kidney cancer patients to participate. This addresses the critical lack of tissue access for rare kidney cancer research.

kccure.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

KCCure partners with RMC Support, an organization founded by Cora Conner to provide information and support for patients with Renal Medullary Carcinoma. KCCure supports RMC awareness campaigns including Change.org petitions and the RMC Support Registry, standing together to advance RMC research efforts.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US umbrella advocacy organization for patients with rare diseases, including rare cancers. Operates research grants and patient assistance programs; comparable as a broader rare-disease advocacy and grant-making infrastructure player.

2American Cancer Society
TypeBroad incumbent
Description

Largest US cancer-focused nonprofit funding multi-cancer research, patient support, and policy advocacy. Comparable as a disease-specific research and support nonprofit, but with vastly broader scope and resources than KCCure.

3Rare Cancer Research Foundation
TypeDirect peer
Description

Nonprofit advancing rare-cancer research including rare kidney cancers, operator of the Pattern.org patient-directed tumor donation platform. Direct KCCure partner addressing the same tissue-access bottleneck for rare kidney cancer research.

TypeBroad incumbent
Description

Largest US kidney-disease nonprofit. While its mission extends well beyond cancer, it includes kidney cancer education and patient resources and was named as a co-partner on Kompass with KCCure — a broad incumbent in overlapping patient-education territory.

TypeDirect peer
Description

Kidney cancer patient advocacy nonprofit focused on accelerating research and patient access to trials. Highly comparable to KCCure in mission scope and listed alongside KCCure as a co-developer of the Kompass digital hub.

TypeBroad incumbent
Description

Established patient-advocacy nonprofit funding research and patient services for a high-mortality cancer. Comparable archetype of a disease-specific advocacy nonprofit that runs patient services and competitive research grants.

TypeDirect peer
Description

Patient-driven support community for renal medullary carcinoma, a rare kidney cancer subtype. KCCure directly partners with RMC Support — analogous grassroots nonprofit structure with rare-subtype focus.

TypeDirect peer
Description

The largest kidney cancer patient advocacy nonprofit in the US, offering education, support, and research funding across all RCC subtypes. Directly comparable as a kidney-cancer-specific advocacy organization and a co-partner with KCCure on the Eisai-led Kompass digital hub.

TypeDirect peer
Description

Largest private funder of pancreatic cancer research with patient-directed research priorities. Comparable funding model that uses donations to direct competitive research grants at high-priority disease areas.

TypeDirect peer
Description

Patient-driven chronic lymphocytic leukemia advocacy nonprofit providing education, expert guidance, and research support. Similar niche-cancer, patient-led advocacy model with research advocacy and physician-scientific advisory board.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KCCure

Patient Advocacy Serviceskccure.org

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit founded in 2016 providing free kidney cancer education, subtype-specific patient communities, clinical trial databases, and peer-reviewed research grants to patients, caregivers, and researchers across all RCC subtypes.

What KCCure does

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit patient advocacy organization founded in 2016 to accelerate kidney cancer research and improve outcomes for patients across all renal cell carcinoma subtypes. The organization serves kidney cancer patients, caregivers, researchers, and clinicians by aggregating educational content, subtype-specific patient communities, clinical trial information, and patient-reported survey data. Cofounded by patients, caregivers, and clinicians — including President Dena Battle and Vice President Dr. Hans Hammers (UT Southwestern) — KCCure operates as a grassroots coalition emphasizing patient-driven, evidence-based advocacy.

The organization's product portfolio spans six interconnected offerings: subtype-specific Facebook patient communities (covering metastatic, localized, papillary, chromophobe, translocation, unclassified RCC, and renal medullary carcinoma); a peer-reviewed research grants program with the Chromophobe RCC Research Program as a flagship ($50,000 annual grants); comprehensive educational resources covering types, stages, grades, adjuvant therapy, and treatments; a non-clear cell RCC clinical trial database; a patient survey research platform whose data has been presented at ASCO and ESMO; and an FDA-approved treatment reference chart. KCCure does not develop proprietary technology; its "platform" is kccure.org supplemented by Facebook groups, functioning as an information aggregation and community hub rather than a technology product.

KCCure's business model is donation-driven: contributions from individuals via website and Facebook campaigns fund both operations and research grants. Notable grant awards include a $100,000 inaugural CAR T-Cell grant to Dana Farber (2017) and recurring $50,000 Chromophobe RCC grants to Brigham and Women's Hospital researchers (FY2022, FY2024). All resources — education, trial listings, community access, grant programs — are provided free. Distribution is entirely direct-to-patient through digital channels globally, with strategic partnerships (Eisai's Kompass hub, Broad Institute's Rare Cancer Dependency Map, RCRF's Pattern.org) extending reach into pharma, research, and tissue-donation ecosystems. The go-to-market motion is community-led: building subtype-specific patient communities, engaging patients in survey research, and amplifying the patient voice at major oncology conferences.

KCCure firmographics

Firmographics
Name
KCCure
Legal name
Kidney Cancer Research Alliance
Website
https://kccure.org
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit founded in 2016 providing free kidney cancer education, subtype-specific patient communities, clinical trial databases, and peer-reviewed research grants to patients, caregivers, and researchers across all RCC subtypes.
Ownership category
akta.pro rank

KCCure industry classification

Industry
Product category
Patient Advocacy Services
NAICS
Voluntary Health Organizations (813212), Social Advocacy Organizations (8133)
SIC
Services-Health Services (8000), Services-Membership Organizations (8600)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGACAL
Public Health & Health Equity Organizations

Keywords

  • Kidney cancer advocacy
  • Patient education resources
  • Research grant funding
  • Patient community support
  • Clinical trial information

Where KCCure is headquartered

Location

Headquarters

HQ city
Leesburg
HQ country
United States
HQ region
North America

Markets served

KCCure business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Others, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Donations: KCCure operates as a 501(c)(3) non-profit organization and raises funds through individual donations, Facebook donation campaigns, and its website donation portal. Donations fund the organization's research grant programs, outreach activities, and operational costs.
  2. Research Grants (Funded by Donations): KCCure funds peer-reviewed kidney cancer research grants using donated funds. The organization has awarded grants including a $100,000 inaugural grant to Dana Farber (CAR T-Cell research) and $50,000 Chromophobe RCC research grants to Brigham and Women's researchers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

KCCure product offering

Product offering

Core offering

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit that provides free kidney cancer patient education resources, subtype-specific online patient communities, peer-reviewed research grant funding (including the Chromophobe RCC Research Program), a non-clear cell clinical trial database, and patient survey research to inform research priorities. The organization aggregates and shares kidney cancer information through its website, Facebook communities, and partnerships with advocacy organizations and pharmaceutical companies. All resources are provided free of charge to patients and caregivers worldwide.

Product overview

KCCure (Kidney Cancer Research Alliance) is a patient-driven, evidence-based kidney cancer advocacy organization offering a suite of interconnected resources including online patient communities for different RCC subtypes, a peer-reviewed research grants program with focus areas like Chromophobe RCC, educational materials on types/stages/treatments, a clinical trial database for non-clear cell subtypes, patient survey research, and an FDA-approved treatment reference chart. The organization operates as a grassroots coalition connecting patients, caregivers, doctors, and researchers to accelerate kidney cancer research and improve patient outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

  • KCCure Patient Communities Online patient communities (primarily Facebook groups) connecting individuals diagnosed with specific kidney cancer subtypes — including clear cell, papillary, chromophobe, translocation, unclassified, renal medullary carcinoma, and localized/metastatic categories — for peer support, information sharing, and clinical trial referrals.
  • KCCure Research Grants Program Peer-reviewed research funding program enabling patients to direct competitive research grants to patient-prioritized kidney cancer research gaps, including the Chromophobe RCC Research Program offering $50,000 awards and the inaugural $100,000 CAR T-Cell grant to Dana Farber.
  • Kidney Cancer Education Resources Free educational materials covering kidney cancer types, stages, grades, treatment options, adjuvant therapy, clinical trials, and a glossary of terms, provided to patients and caregivers through the KCCure website.
  • Non-Clear Cell RCC Clinical Trial Database Comprehensive listing of active and enrolling clinical trials specifically for non-clear cell renal cell carcinoma subtypes, including NCT trial IDs, histology, treatments, phases, and locations, published on the KCCure website.
  • Patient Survey Data Platform Patient-driven survey research program including the 2019 Kidney Cancer Patient Survey, COVID-19/Kidney Cancer Patient Survey, and COVID-19 Vaccine surveys, generating patient-reported outcome and treatment-preference data that informs research priorities and is presented at major oncology conferences.
  • FDA-Approved Kidney Cancer Treatment Chart Reference chart listing all FDA-approved treatments for metastatic renal cell carcinoma with brand/generic names, drug companies, approval dates, and line of therapy information, published as a free resource on the KCCure website.

Quantifiable outcome

  • Chromophobe patient community grew by more than 70 percent since the KCCure Chromophobe Program launched in 2020
  • +3 more outcomes

Companies that use KCCure

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

KCCure technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

KCCure partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • EisaicoreStrategic or Co-development Partner · 26 February 2026Eisai partnered with KCCure and three other advocacy organizations (KidneyCAN, Kidney Cancer Association, National Kidney Foundation) to launch Kompass, an unbranded digital hub that aggregates kidney cancer support resources for patients and caregivers. The platform features around four dozen resources including educational guides, videos, helplines, peer mentoring, and patient testimonials, personalized based on user responses to three questions about their role and needs. KCCure contributed its expertise in patient-centered resources and community needs to this initiative.
  • KidneyCANcoreStrategic or Co-development Partner · 26 February 2026KidneyCAN is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers. KCCure and KidneyCAN contributed to the aggregation of support resources on the platform.
  • Kidney Cancer AssociationcoreStrategic or Co-development Partner · 26 February 2026The Kidney Cancer Association is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers, providing educational resources and support materials on the platform.
  • National Kidney FoundationcoreStrategic or Co-development Partner · 26 February 2026The National Kidney Foundation is one of the four advocacy organizations that partnered with Eisai and KCCure to launch the Kompass digital hub for kidney cancer patients and caregivers, contributing kidney cancer support resources to the platform.
  • Brigham and Women's HospitalcoreStrategic or Co-development Partner · 29 March 2023KCCure awarded Dr. Elizabeth Henske and Dr. Carmen Priolo from Brigham and Women's Hospital the FY2022 KCCure Chromophobe Research Grant of $50,000 for their proposal: Role of Cysteine Homeostasis and Ferroptosis in the Therapy of Chromophobe RCC. This grant is part of the KCCure Chromophobe RCC Research Program. Dr. Henske received a second grant in 2024 for Targeting KIT in Chromophobe Kidney Cancer.
  • Dana Farber Cancer CentercoreStrategic or Co-development Partner · 22 June 2017KCCure awarded its inaugural research grant of $100,000 to Dr. Wayne Marasco at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures. This was described as a milestone for KCCure and for kidney cancer research as a whole.
  • Broad InstitutemajorStrategic or Co-development PartnerKCCure's Director of Patient Engagement Laura Loughlin attended the Broad Institute's Pre-Launch Workshop for the Rare Cancer Dependency Map Initiative. The initiative provides a patient-driven research platform seeking treatments for rare kidney cancers. KCCure promotes and supports this research effort as part of its mission to advance rare subtype research.
  • Rare Cancer Research Foundation (RCRF)majorStrategic or Co-development PartnerKCCure partners with the Rare Cancer Research Foundation (RCRF) and promotes Pattern.org, an online patient-directed consent platform that allows patients to authorize donation of fresh tumor tissue for research. KCCure actively encourages eligible kidney cancer patients to participate. This addresses the critical lack of tissue access for rare kidney cancer research.
  • RMC SupportminorStrategic or Co-development PartnerKCCure partners with RMC Support, an organization founded by Cora Conner to provide information and support for patients with Renal Medullary Carcinoma. KCCure supports RMC awareness campaigns including Change.org petitions and the RMC Support Registry, standing together to advance RMC research efforts.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

KCCure competitors and assessment

Company assessment

Broad incumbents

  • National Organization for Rare Disorders (NORD): US umbrella advocacy organization for patients with rare diseases, including rare cancers. Operates research grants and patient assistance programs; comparable as a broader rare-disease advocacy and grant-making infrastructure player.
  • American Cancer Society: Largest US cancer-focused nonprofit funding multi-cancer research, patient support, and policy advocacy. Comparable as a disease-specific research and support nonprofit, but with vastly broader scope and resources than KCCure.
  • National Kidney Foundation: Largest US kidney-disease nonprofit. While its mission extends well beyond cancer, it includes kidney cancer education and patient resources and was named as a co-partner on Kompass with KCCure — a broad incumbent in overlapping patient-education territory.
  • Pancreatic Cancer Action Network (PanCAN): Established patient-advocacy nonprofit funding research and patient services for a high-mortality cancer. Comparable archetype of a disease-specific advocacy nonprofit that runs patient services and competitive research grants.

Direct peers

  • Rare Cancer Research Foundation: Nonprofit advancing rare-cancer research including rare kidney cancers, operator of the Pattern.org patient-directed tumor donation platform. Direct KCCure partner addressing the same tissue-access bottleneck for rare kidney cancer research.
  • KidneyCAN: Kidney cancer patient advocacy nonprofit focused on accelerating research and patient access to trials. Highly comparable to KCCure in mission scope and listed alongside KCCure as a co-developer of the Kompass digital hub.
  • Renal Medullary Carcinoma Support Network: Patient-driven support community for renal medullary carcinoma, a rare kidney cancer subtype. KCCure directly partners with RMC Support — analogous grassroots nonprofit structure with rare-subtype focus.
  • Kidney Cancer Association: The largest kidney cancer patient advocacy nonprofit in the US, offering education, support, and research funding across all RCC subtypes. Directly comparable as a kidney-cancer-specific advocacy organization and a co-partner with KCCure on the Eisai-led Kompass digital hub.
  • Lustgarten Foundation: Largest private funder of pancreatic cancer research with patient-directed research priorities. Comparable funding model that uses donations to direct competitive research grants at high-priority disease areas.
  • CLL Society: Patient-driven chronic lymphocytic leukemia advocacy nonprofit providing education, expert guidance, and research support. Similar niche-cancer, patient-led advocacy model with research advocacy and physician-scientific advisory board.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

KCCure social profiles

Digital presence

KCCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KCCure leadership team

Management profile

Number of profiles

Profiles4 records

KCCure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KCCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KCCure

What does KCCure do?

KCCure (Kidney Cancer Research Alliance) is a 501(c)(3) nonprofit that provides free kidney cancer patient education resources, subtype-specific online patient communities, peer-reviewed research grant funding (including the Chromophobe RCC Research Program), a non-clear cell clinical trial database, and patient survey research to inform research priorities. The organization aggregates and shares kidney cancer information through its website, Facebook communities, and partnerships with advocacy organizations and pharmaceutical companies. All resources are provided free of charge to patients and caregivers worldwide.

Is KCCure a public or private company?

KCCure is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was KCCure founded?

KCCure was founded in 2016. It employs 1 to 10 people.

Where is KCCure based?

KCCure is headquartered in Leesburg, United States, in the North America region.

How does KCCure make money?

Two revenue lines are on record. Donations are the primary driver. The others are research Grants (Funded by Donations).

Who are KCCure's main competitors?

Broad incumbents on record are National Organization for Rare Disorders (NORD), American Cancer Society, National Kidney Foundation and Pancreatic Cancer Action Network (PanCAN). Direct peers are Rare Cancer Research Foundation, KidneyCAN, Renal Medullary Carcinoma Support Network, Kidney Cancer Association, Lustgarten Foundation and CLL Society.

Does KCCure have an API?

No public API is recorded for KCCure.

What industry is KCCure in?

KCCure's product category is Patient Advocacy Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGACAL, Public Health & Health Equity Organizations. Its NAICS code is 813212 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales